How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

264 results for

Adamantane

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Saxagliptin + saxagliptin/metformin: Addendum to Commission A16-42 + A16-43

to Commission A16-42 + A16-43] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 464. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Dipeptides; Humans; Metformin Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685

2016 Health Technology Assessment (HTA) Database.

42. Molecular characterization of influenza A(H1N1)pdm09 in Cameroon during the 2014-2016 influenza seasons. (PubMed)

(HA, NA and M) of Cameroon strains were studied. The phylogenetic tree of the coding nucleotide sequences was generated by MEGA version 6.0 using a Maximum Likelihood method. The NA and M protein coding sequences were analyzed for the reported genetic markers of resistance against neuraminidase inhibitors and adamantanes, while predicted vaccine efficacy was estimated using the Pepitope method. Overall 39 strains were obtained. Phylogenetic analysis of the HA gene of influenza A(H1N1)pdm09 showed

Full Text available with Trip Pro

2019 PLoS ONE

43. Viral Factors Associated With the High Mortality Related to Human Infections With Clade 2.1 Influenza A/H5N1 Virus in Indonesia. (PubMed)

analyses were performed in specimens from 180 H5N1 patients, representing 90% of all Indonesian patients and 20% of reported H5N1-infected patients globally.H5N1 RNA was quantified in available upper- and lower-respiratory tract specimens as well as fecal and blood samples from 180 patients with confirmed infection between 2005 and 2017. Mutations in the neuraminidase and M2 genes that confer resistance to oseltamivir and adamantanes were assessed. Fatal and nonfatal cases were compared.High viral RNA

2019 Clinical Infectious Diseases

44. Vildagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Vildagliptin – nutzenbewertung gemäß § 35a SGB V. [Vildagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 178. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2s; Dipeptidyl-Peptidase IV Inhibitors

2014 Health Technology Assessment (HTA) Database.

45. Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Metformins; Nitriles; Pyrrolidines Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32014000013 Date abstract record published 09/01/2014 Health Technology Assessment (HTA) database

2014 Health Technology Assessment (HTA) Database.

46. Saxagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Adamantane; Diabetes Mellitus, Type 2; Dipeptidess; Dipeptidyl-Peptidase IV Inhibitors Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32014000037 Date abstract record published 10/01/2014 Health Technology Assessment (HTA) database Copyright © 2019 Institut

2014 Health Technology Assessment (HTA) Database.

47. Saxagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Saxagliptin – nutzenbewertung gemäß § 35a SGB V. [Saxagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 174. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2s; Dipeptides; Dipeptidyl-Peptidase IV

2014 Health Technology Assessment (HTA) Database.

48. Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2s; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Metformin Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32014000017 Date abstract record

2014 Health Technology Assessment (HTA) Database.

49. Saxagliptin (Onglyza®)

MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX Email: AWTTC@wales.nhs.uk AccessionNumber 32013001030 Date abstract record published 23/12/2013 Health Technology

2014 Health Technology Assessment (HTA) Database.

50. Addendum to commission A13-17 (vildagliptin/metformin)

. Addendum zum auftrag A13-17 (vildagliptin/metformin). [Addendum to commission A13-17 (vildagliptin/metformin)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 189. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Metformin; Nitriles; Pyrrolidines Language Published German Country of organisation Germany English summary There is no English

2014 Health Technology Assessment (HTA) Database.

51. Addendum to Commission A13-16 (vildagliptin)

to Commission A13-16 (vildagliptin)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 188. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2s; Dipeptidyl-Peptidase IV Inhibitors; Nitriles; Pyrrolidines Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne

2014 Health Technology Assessment (HTA) Database.

52. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus

and a sulfonylurea and for whom insulin is not an option. 2. Drug plan costs for saxagliptin should not exceed the cost of other dipeptidyl peptidase-4 (DPP-4) inhibitors. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2s; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Canadian

2014 Health Technology Assessment (HTA) Database.

53. Clinical review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus

complications of diabetes, specifically in patients who were unable to use insulin. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitorss Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600

2014 Health Technology Assessment (HTA) Database.

54. Pharmacoeconomic review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus

Subject indexing assigned by CRD MeSH Adamantane; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitorss Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000844 Date

2014 Health Technology Assessment (HTA) Database.

55. Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms. (PubMed)

. We specifically examine three factors and their effect on the emergence of drug-resistant mutants: antiviral mechanism, the immune response, and surface proteins. We find that adamantanes, because they act at the start of the replication cycle to prevent infection, are less likely to produce drug-resistant mutants than NAIs, which act at the end of the replication cycle. A mismatch between surface proteins and internal RNA results in drug-resistant mutants being less likely to emerge

Full Text available with Trip Pro

2017 PLoS ONE

56. Adapentpronitrile, a New Dipeptidyl Peptidase-IV Inhibitor, Ameliorates Diabetic Neuronal Injury Through Inhibiting Mitochondria-Related Oxidative Stress and Apoptosis (PubMed)

Adapentpronitrile, a New Dipeptidyl Peptidase-IV Inhibitor, Ameliorates Diabetic Neuronal Injury Through Inhibiting Mitochondria-Related Oxidative Stress and Apoptosis Our previous studies indicated that adapentpronitrile, a new adamantane-based dipeptidyl peptidase-IV (DPP-IV) inhibitor, has a hypoglycemic effect and ameliorates rat pancreatic β cell dysfunction in type 2 diabetes mellitus through inhibiting DPP-IV activity. However, the effect of adapentpronitrile on the neurodegenerative

Full Text available with Trip Pro

2018 Frontiers in cellular neuroscience

57. New endoperoxides highly active in vivo and in vitro against artemisinin-resistant Plasmodium falciparum. (PubMed)

. Ring survival and mature stage survival assays were performed against artemisinin-resistant and artemisinin-sensitive P. falciparum strains. Cytotoxicity was evaluated against mammalian cell lines V79 and HepG2, using the MTT assay.The synthesis and anti-malarial activity of 21 new endoperoxide-derived compounds is reported, where the peroxide pharmacophore is part of a trioxolane (ozonide) or a tetraoxane moiety, flanked by adamantane and a substituted cyclohexyl ring. Eight compounds exhibited

Full Text available with Trip Pro

2018 Malaria journal

58. Blockade of soluble epoxide hydrolase attenuates post-ischemic neuronal hyperexcitation and confers resilience against stroke with TrkB activation (PubMed)

a permanent middle cerebral artery occlusion (MCAO) model in adult wild-type mice with the sEH inhibitor 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA) post-treatment and in sEH knockout (sEH KO) mice. We found that sensorimotor recovery was significantly enhanced after MCAO in both AUDA-treated and sEH KO mice, with decreased sEH activity and brain infarction. Decreased post-ischemic long-term potentiation (iLTP) was observed in an ex vivo hippocampal oxygen-glucose deprivation model. Tropomyosin

Full Text available with Trip Pro

2018 Scientific reports

59. Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases (PubMed)

and evaluated using various assays including in vitro HDAC binding assays and PET imaging in rodents and non-human primates. Although most compounds do not readily cross the blood-brain barrier, adamantane-conjugated radioligands tend to show good brain uptake. Until now, only one HDAC radioligand has been tested clinically in a brain PET study. Further PET imaging studies to clarify age-related and disease-related changes in HDACs in disease models and humans will increase our understanding of the roles

Full Text available with Trip Pro

2018 Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry

60. Palmitic Acid Methyl Ester and Its Relation to Control of Tone of Human Visceral Arteries and Rat Aortas by Perivascular Adipose Tissue (PubMed)

. These effects were abolished by XE991 (30 μM), but not 4-aminopyridine (2 mM) or NDGA (10 μM), a lipoxygenases inhibitor. The cytochrome P450 epoxygenase inhibitor 17-octadecynoic acid (ODYA 10 μM) and the soluble epoxide hydrolase inhibitor 12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA 10 μM) slightly decreased PAME relaxations. PAME up to 10 μM failed to induce relaxations of PVAT-removed human mesenteric arteries. 5-HT induced endogenous PAME release from rat peri-aortic adipose tissue, but not from

Full Text available with Trip Pro

2018 Frontiers in physiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>